Showing results (41-50 of 51) with videos related to
Sort By:
Pageof 6
Journal for Immunotherapy of Cancer|March 1, 2024
Mitochondria-targeted photodynamic therapy triggers GSDME-mediated pyroptosis and sensitizes anti-PD-1 therapy in colorectal cancerYun Zhou, Wenyao Zhang, Boda Wang, et al.RSC Advances|February 14, 2020
A self-internalizing mitochondrial TSPO targeting imaging probe for fluorescence, MRI and EMLynn E Samuelson, Bernard M Anderson, Mingfeng Bai, et al.Plos One|December 19, 2009
Binding of NIR-conPK and NIR-6T to astrocytomas and microglial cells: evidence for a protein related to TSPOMichelle Sexton, Grace Woodruff, Eiron Cudaback, et al.Plos One|November 28, 2013
Cannabinoid CB2 receptors regulate central sensitization and pain responses associated with osteoarthritis of the knee jointJames J Burston, Devi Rani Sagar, Pin Shao, et al.Journal of Medicinal Chemistry|June 29, 2019
Discovery of 2-(4-Chloro-3-(trifluoromethyl)phenyl)-<i>N</i>-(4-((6,7-dimethoxyquinolin-4-yl)oxy)phenyl)acetamide (CHMFL-KIT-64) as a Novel Orally Available Potent Inhibitor against Broad-Spectrum Mutants of c-KIT Kinase for Gastrointestinal Stromal TumorsYun Wu, Beilei Wang, Junjie Wang, et al.Journal of Medicinal Chemistry|May 4, 2019
Discovery of ( E)- N<sup>1</sup>-(3-Fluorophenyl)- N<sup>3</sup>-(3-(2-(pyridin-2-yl)vinyl)-1 H-indazol-6-yl)malonamide (CHMFL-KIT-033) as a Novel c-KIT T670I Mutant Selective Kinase Inhibitor for Gastrointestinal Stromal Tumors (GISTs)Xuesong Liu, Beilei Wang, Cheng Chen, et al.Cancer Letters|January 27, 2019
Repurposing cabozantinib to GISTs: Overcoming multiple imatinib-resistant cKIT mutations including gatekeeper and activation loop mutants in GISTs preclinical modelsTingting Lu, Cheng Chen, Aoli Wang, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 16, 2020
TSPO-targeted PET and Optical Probes for the Detection and Localization of Premalignant and Malignant Pancreatic LesionsAllison S Cohen, Jun Li, Matthew R Hight, et al.Therapeutic Advances in Medical Oncology|June 18, 2019
Axitinib overcomes multiple imatinib resistant cKIT mutations including the gatekeeper mutation T670I in gastrointestinal stromal tumorsFeiyang Liu, Fengming Zou, Cheng Chen, et al.Journal of Medicinal Chemistry|August 23, 2016
Discovery of N-((1-(4-(3-(3-((6,7-Dimethoxyquinolin-3-yl)oxy)phenyl)ureido)-2-(trifluoromethyl)phenyl)piperidin-4-yl)methyl)propionamide (CHMFL-KIT-8140) as a Highly Potent Type II Inhibitor Capable of Inhibiting the T670I "Gatekeeper" Mutant of cKIT KinaseBinhua Li, Aoli Wang, Juan Liu, et al.Pageof 6